Litigation Details for Belcher Pharmaceuticals, LLC v. International Medication Systems, Limited (D. Del. 2018)

Belcher Pharmaceuticals, LLC v. International Medication Systems, Limited (D. Del. 2018)

Docket		Date Filed	2018-06-28
Court	District Court, D. Delaware	Date Terminated	2022-03-28
Cause	35:271 Patent Infringement	Assigned To	Vacant Judgeship
Jury Demand	Plaintiff	Referred To	Christopher J. Burke
Patents	9,283,197
Link to Docket	External link to docket

Details for Belcher Pharmaceuticals, LLC v. International Medication Systems, Limited (D. Del. 2018)

Date Filed	Document No.	Description	Snippet	Link To Document
2018-06-28				External link to document
2018-06-28	1	Complaint	rg ery. 15. U nited Sta tes Patent No. 9,283,197 (“‘197 Pa tent”, Exhibit A) is titled “… COMPLAINT for PATENT INFRINGEMENT filed with Jury Demand against International Medication Systems…has infring ed one or m ore claim s of the ‘197 Patent by su bm itting NDA No. 211363 seek ing FDA approval…2018 28 March 2022 1:18-cv-00960 830 Patent Plaintiff District Court, D. Delaware	External link to document
2018-06-28	3	Patent/Trademark Report to Commissioner	the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,283,197. (nmg) (Entered: 06…2018 28 March 2022 1:18-cv-00960 830 Patent Plaintiff District Court, D. Delaware	External link to document

Belcher Pharmaceuticals v. International Medication Systems: Patent Litigation Summary and Analysis

Last updated: September 28, 2026

Belcher Pharmaceuticals, LLC sued International Medication Systems, Limited in the U.S. District Court for the District of Delaware after IMS submitted an abbreviated new drug application seeking approval for a generic epinephrine injection. The dispute centered on Belcher’s U.S. Patent No. 9,283,197, covering certain low-dose epinephrine formulations. The case was resolved without a public merits judgment on infringement or validity. Public docket materials do not disclose the material terms of the parties’ resolution. [1][2]

What was Belcher Pharmaceuticals v. International Medication Systems about?

Belcher’s complaint alleged that IMS’s ANDA product would infringe claims of U.S. Patent No. 9,283,197 under the Hatch-Waxman Act. The patent relates to pharmaceutical compositions containing epinephrine with specified formulation characteristics, including pH and stability parameters. [1][3]

Item	Case detail
Case	Belcher Pharmaceuticals, LLC v. International Medication Systems, Limited
Court	U.S. District Court for the District of Delaware
Civil action	No. 1:18-cv-00960
Filed	2018
Plaintiff	Belcher Pharmaceuticals, LLC
Defendant	International Medication Systems, Limited
Technology	Epinephrine injection formulation
Primary patent identified in the dispute	U.S. Patent No. 9,283,197
Procedural basis	Hatch-Waxman patent litigation following an ANDA Paragraph IV certification
Outcome	Resolved without a public merits decision
Public settlement terms	Not disclosed

Belcher’s product was an epinephrine injection intended for emergency treatment of severe allergic reactions and related acute conditions. IMS sought approval for a generic version of the same active ingredient and dosage form.

What patent protected Belcher’s epinephrine injection?

The principal patent at issue was U.S. Patent No. 9,283,197, titled “Epinephrine Formulation.” The patent was assigned to Belcher Pharmaceuticals and claimed epinephrine compositions with formulation properties designed to maintain product stability and suitability for injection. [3]

U.S. Patent No. 9,283,197

Field	Information
Patent number	9,283,197
Title	Epinephrine Formulation
Assignee	Belcher Pharmaceuticals, LLC
Technology	Stable epinephrine pharmaceutical composition
Relevant product	Epinephrine injection
Patent type	Formulation and composition patent
Litigation role	Asserted against IMS’s ANDA product
Expected ordinary expiration	Approximately 2029, subject to patent-term adjustment and statutory calculation

The patent estate surrounding Belcher’s epinephrine product also included related continuation filings, including U.S. Patent No. 9,610,316. The IMS case is principally associated with the ’197 patent in the public litigation record. [3][4]

The claims were commercially important because generic epinephrine products must satisfy narrow formulation, stability, pH, preservative and manufacturing requirements. A generic applicant may avoid infringement by using a materially different formulation, but the product must still satisfy FDA quality and stability requirements.

What was IMS’s Paragraph IV challenge?

IMS’s ANDA apparently included a Paragraph IV certification asserting that the relevant Belcher patent was invalid, unenforceable or would not be infringed by the proposed generic product. A Paragraph IV certification gives the patent holder 45 days to bring an infringement action. A timely suit triggers the Hatch-Waxman 30-month stay of FDA approval, subject to statutory exceptions and court orders. [1][5]

The case therefore had two immediate commercial consequences:

1. IMS could not ordinarily obtain final FDA approval during the statutory stay.
2. Belcher obtained an opportunity to enforce its formulation patent before generic approval.

The public record does not establish that the court adjudicated the specific technical differences between IMS’s proposed formulation and Belcher’s patented formulation. The case did not produce a reported claim-construction ruling, infringement judgment or invalidity judgment.

What was the litigation timeline?

Date or period	Event
Before 2018	Belcher developed and commercialized an epinephrine injection product and obtained related patent protection.
2018	IMS submitted an ANDA for a generic epinephrine injection and served a Paragraph IV notice on Belcher.
2018	Belcher filed Civil Action No. 1:18-cv-00960 in the District of Delaware.
2018-2019	The parties litigated the Hatch-Waxman dispute and negotiated resolution.
Resolution period	The action ended without a public merits ruling.
After resolution	No publicly reported decision in this action determined that the ’197 patent was valid, infringed or enforceable against IMS.

The docket does not show a trial verdict or final judgment establishing that IMS infringed the patent. It also does not establish that the patent was held invalid in this action.

Did Belcher win or lose the IMS case?

The IMS case should be classified as a non-merits resolution rather than a judicial victory for either side.

Belcher did not receive a publicly reported infringement judgment. IMS did not receive a publicly reported invalidity judgment. The case outcome therefore provides limited precedent on the enforceability of Belcher’s patent estate.

A dismissal or stipulated termination in a Hatch-Waxman case does not, by itself, establish:

• That the patent claims were valid;
• That the proposed generic product infringed;
• That the product could launch before patent expiration;
• That Belcher’s patent estate was enforceable against other ANDA applicants; or
• That the parties reached a particular launch date.

Those questions depend on the terms of the resolution and on separate litigation involving other generic applicants.

What patent litigation affected Belcher’s epinephrine patent estate?

The more consequential reported litigation involving Belcher’s epinephrine patent was Belcher Pharmaceuticals, LLC v. Hospira, Inc. In that case, the District of Delaware held that the asserted patent was unenforceable because of inequitable conduct before the U.S. Patent and Trademark Office. The court found that material information concerning prior art and formulation development had not been disclosed to the USPTO. [6]

The Federal Circuit later affirmed the inequitable-conduct judgment. [7]

How does the Hospira case affect the IMS analysis?

The Hospira decision is relevant but does not convert the IMS case into an adjudicated invalidity or unenforceability judgment. The cases involved different defendants and separate procedural records. The Hospira ruling may have weakened Belcher’s ability to enforce the same patent claims against other generic manufacturers, but its direct preclusive effect depends on the asserted claims, parties, judgment language and procedural posture.

For commercial diligence, the distinction matters:

Issue	IMS case	Hospira case
Defendant	International Medication Systems	Hospira
Public merits ruling	No reported merits ruling	Yes
Principal issue	ANDA infringement dispute	Enforceability and inequitable conduct
Patent relevance	Belcher epinephrine formulation patent	Belcher epinephrine formulation patent
Public outcome	Non-merits resolution	Patent held unenforceable
Direct precedent against IMS	Limited	Not a direct judgment against IMS

What was the FDA and Orange Book status?

Belcher’s epinephrine product was approved through the FDA’s NDA pathway, while IMS pursued approval through an ANDA. The Orange Book patent-listing framework allowed Belcher to list qualifying patents associated with its approved drug product. [5][8]

The relevant regulatory structure was:

• Belcher: NDA holder for the branded or reference epinephrine injection.
• IMS: ANDA applicant for a therapeutically equivalent generic product.
• Patent certification: Paragraph IV challenge to the listed patent.
• Litigation effect: A timely patent suit generally triggered the statutory 30-month stay.
• FDA approval: Approval timing depended on the litigation resolution, statutory exclusivity, patent status and any settlement restrictions.

The public record for the IMS case does not establish the exact FDA approval date for IMS’s ANDA, the precise end of the 30-month stay, or whether the resolution included a licensed launch date.

What generic entry risks did IMS create?

IMS represented a conventional ANDA threat to Belcher’s epinephrine franchise. The principal risk categories were:

Formulation substitution

Epinephrine is chemically sensitive and requires tight control of oxidation, pH, preservatives and packaging. A generic applicant may seek a design-around formulation, but any changes must remain pharmaceutically acceptable and meet FDA specifications.

Patent enforcement risk

Belcher’s patent position could delay approval if the asserted claims survived litigation. The later Hospira inequitable-conduct ruling materially reduced the practical strength of the ’197 patent against competing generic applicants.

Settlement risk

The absence of public settlement terms prevents a definitive conclusion on whether IMS received:

• An agreed launch date;
• A license;
• A covenant not to sue;
• A product-specific carve-out;
• A royalty obligation; or
• A restriction tied to patent expiration.

Regulatory substitution

If IMS obtained FDA approval and met state substitution requirements, pharmacy-level substitution could pressure Belcher’s price and volume. The commercial impact would depend on IMS’s approval status, supply capacity, contracting strategy and the number of competing ANDA applicants.

How strong was Belcher’s patent estate?

Belcher’s estate had meaningful technical relevance because it targeted the formulation rather than only the active ingredient. Epinephrine itself is an old compound, so composition and method-of-use claims directed broadly to epinephrine would face substantial prior-art exposure. Formulation claims can provide more focused protection but are vulnerable to:

• Anticipation by earlier epinephrine products;
• Obviousness based on known pH and antioxidant ranges;
• Written-description and enablement challenges;
• Noninfringing formulation design-arounds; and
• Inequitable-conduct allegations based on undisclosed prior art.

The Hospira judgment was the most important public development affecting the estate’s enforceability. It showed that the litigation risk extended beyond claim scope and prior art to the prosecution conduct surrounding the patent. [6][7]

Patent-strength assessment

Factor	Assessment
Active ingredient protection	Weak because epinephrine is long-established
Formulation relevance	Meaningful, particularly for defined stability and pH parameters
Design-around risk	Material
Orange Book leverage	Available through listed patent protection
Enforceability after Hospira	Significantly impaired for the adjudicated patent
Litigation precedent	Strong adverse precedent from inequitable-conduct ruling
Biosimilar exposure	Not applicable; epinephrine is a small-molecule drug
Manufacturing barrier	Moderate; sterile injectable manufacturing and stability validation remain operational barriers

Were biosimilar risks relevant?

No. This was a small-molecule Hatch-Waxman dispute, not a biologics competition under the Biologics Price Competition and Innovation Act.

The relevant competitors were ANDA filers and generic injectable manufacturers. Biosimilar concepts such as reference-product exclusivity, the Purple Book and the BPCIA patent dance did not apply.

What were the commercial and revenue implications?

Public filings do not provide a reliable standalone revenue figure for Belcher’s epinephrine product in connection with this litigation. The economic exposure was nevertheless concentrated in several areas:

• Loss of pricing power after generic approval;
• Reduced hospital and distributor purchasing leverage;
• Potential substitution away from Belcher’s product;
• Lower value of formulation patents and licensing rights;
• Increased litigation costs; and
• Reduced negotiating leverage in later ANDA disputes.

IMS’s potential entry would have had a greater effect if it were the first approved generic. Multiple generic entrants would likely have accelerated price erosion, while a single entrant under a negotiated launch date could have produced a more limited initial impact.

What does the case mean for generic launch analysis?

The case does not support a confirmed early-entry date for IMS. Because the resolution terms are not public, a launch scenario cannot be inferred solely from the docket termination.

The relevant scenarios were:

Scenario	Commercial result
No approval during patent dispute	Belcher retains market exclusivity pending litigation or regulatory resolution
Settlement with delayed launch	IMS enters on a negotiated date, often before nominal patent expiration
Settlement with immediate launch	Generic competition begins after regulatory approval and settlement completion
Patent defeat or unenforceability ruling	Multiple generic applicants may accelerate entry
Design-around approval	Generic entry can occur without direct infringement of the asserted claims

The later Hospira decision increased the probability of generic competition by weakening enforceability of the relevant patent. It did not, however, establish IMS’s specific launch rights.

Key Takeaways

• Belcher sued IMS in the District of Delaware over an ANDA for generic epinephrine injection.
• The principal patent was U.S. Patent No. 9,283,197, directed to epinephrine formulation technology.
• The case ended without a public merits judgment on IMS’s infringement or the patent’s validity.
• Public sources do not disclose the material settlement or resolution terms.
• The case was a Hatch-Waxman small-molecule dispute, not a biosimilar case.
• Belcher’s patent position was materially weakened by the later Hospira inequitable-conduct ruling.
• Any IMS launch date, license, royalty or market-entry restriction should not be treated as established without the confidential resolution agreement or FDA approval record.

FAQs About Belcher Pharmaceuticals v. International Medication Systems

Was IMS accused of infringing an epinephrine patent?

Yes. Belcher alleged that IMS’s ANDA product would infringe U.S. Patent No. 9,283,197.

Did Belcher obtain an injunction against IMS?

No publicly reported merits injunction appears in the case record.

Did the court invalidate Belcher’s epinephrine patent in the IMS case?

No. The IMS action ended without a public invalidity decision.

Did IMS launch a generic epinephrine product?

The public litigation record does not establish the precise timing or conditions of any IMS launch.

Does the Hospira decision automatically invalidate the patent for all defendants?

No. The Hospira judgment directly concerned that litigation and defendant. Its broader effect depends on the patent claims, judgment, procedural posture and later litigation.

References

1. U.S. District Court for the District of Delaware. (2018). Belcher Pharmaceuticals, LLC v. International Medication Systems, Limited, No. 1:18-cv-00960. PACER/Court docket.

2. CourtListener. (n.d.). Belcher Pharmaceuticals, LLC v. International Medication Systems, Limited, No. 1:18-cv-00960. https://www.courtlistener.com/

3. U.S. Patent and Trademark Office. (2016). U.S. Patent No. 9,283,197, Epinephrine formulation. https://patents.google.com/patent/US9283197B2/en

4. U.S. Patent and Trademark Office. (2017). U.S. Patent No. 9,610,316, Epinephrine formulation. https://patents.google.com/patent/US9610316B2/en

5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

6. U.S. District Court for the District of Delaware. (2020). Belcher Pharmaceuticals, LLC v. Hospira, Inc., inequitable-conduct decision.

7. U.S. Court of Appeals for the Federal Circuit. (2021). Belcher Pharmaceuticals, LLC v. Hospira, Inc., appellate decision.

8. U.S. Food and Drug Administration. (2018). Epinephrine injection approval and labeling materials. https://www.accessdata.fda.gov/-drugsatfda_docs/label/2018/209862s000lbl.pdf